Published in Leukemia on May 06, 2013
Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson. Leukemia (2013) 1.39
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol (2014) 1.38
Clinical development of demethylating agents in hematology. J Clin Invest (2014) 1.07
Epigenetics of myelodysplastic syndromes. Leukemia (2013) 0.92
Epigenetics in the hematologic malignancies. Haematologica (2014) 0.83
Expanding role of lenalidomide in hematologic malignancies. Cancer Manag Res (2015) 0.83
Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients. Leukemia (2014) 0.75
Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. J Blood Med (2014) 0.75
Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia (2004) 1.90
The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia (2008) 1.89
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia (2005) 1.72
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia (2013) 1.71
A pilot study of bendamustine in elderly patients with high-risk MDS and AML. Leuk Lymphoma (2007) 1.58
Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant (2005) 1.57
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia (2012) 1.57
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia (2010) 1.48
Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia (1992) 1.45
Pericardial effusion in chronic myelomonocytic leukemia (CMML): a case report and review of the literature. Leuk Res (2000) 1.42
Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia. Cytotherapy (2004) 1.41
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia (2013) 1.39
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia (2013) 1.37
Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol (2001) 1.30
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia (2004) 1.28
Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol (2010) 1.26
Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia (2013) 1.23
The 5q- syndrome. Hematology (2004) 1.23
Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol (2009) 1.22
Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia (2007) 1.20
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia (2012) 1.07
The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia (2006) 1.04
Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol (2005) 1.04
Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol (2002) 1.00
Acute basophilic leukemia. Eur J Haematol (2001) 0.97
5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant (2009) 0.96
Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance. Leukemia (2011) 0.96
Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Leukemia (2013) 0.95
[Imaging of supradiaphragmatic manifestations of extranodal non-Hodgkin's lymphoma]. Radiologe (2002) 0.95
A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Ann Oncol (2010) 0.94
The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML. Leukemia (2003) 0.92
Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts. Leukemia (2012) 0.90
Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia (2013) 0.89
The JAK2 V617F mutation is rare in RARS but common in RARS-T. Leukemia (2006) 0.89
Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma. Leuk Res (2001) 0.86
Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res (1998) 0.85
Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine. Ann Hematol (2005) 0.84
Acute promyelocytic leukemia and pregnancy. Eur J Haematol (2000) 0.84
Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score. Leukemia (1994) 0.83
Clonal relationship between langerhans cell histiocytosis and myeloid sarcoma. Leukemia (2012) 0.83
[Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes]. Beitr Infusionsther (1992) 0.83
Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion. Acta Haematol (2005) 0.83
Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide. Leukemia (2011) 0.82
Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol (2002) 0.81
Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma. Ann Hematol (1999) 0.81
The German competence network 'Acute and chronic leukemias'. Leukemia (2004) 0.81
Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia (2002) 0.81
Thalidomide for the treatment of idiopathic myelofibrosis. Eur J Haematol (2004) 0.79
Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol (2002) 0.79
Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports. Leuk Lymphoma (2002) 0.79
MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500 x 10(9)/l. Ann Hematol (2007) 0.78
Transdermal fentanyl during high-dose chemotherapy and autologous stem cell support. Oncol Rep (2000) 0.77
Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts. Leukemia (2013) 0.77
Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. Leukemia (2003) 0.77
Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes. Crit Rev Oncol Hematol (2010) 0.77
[Dynamic contrast-enhanced MRI for evaluating bone marrow microcirculation in malignant hematological diseases before and after thalidomide therapy]. Radiologe (2002) 0.77
Patient-controlled versus staff-controlled analgesia with pethidine after allogeneic bone marrow transplantation. Pain (1998) 0.77
Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals. Infection (2013) 0.76
Improving the prognostic evaluation of patients with lower risk myelodysplastic syndromes. Leukemia (2008) 0.76
Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis. Br J Haematol (2000) 0.76
Prevention of postsplenectomy sepsis. Hematol J (2001) 0.75
[Splenectomy for thrombocytopenic purpura. Retrospective analysis of the postoperative course]. Chirurg (2005) 0.75
Pseudomonas aeruginosa orbital phlegmon in a patient treated for myelodysplastic syndrome with concomitant Sjögren's syndrome. Eur J Med Res (1999) 0.75
[Myelodysplastic syndromes]. Internist (Berl) (1998) 0.75
Expression of cd34 and p-glycoprotein - prognostic-significance in primary myelodysplastic syndromes. Int J Oncol (1995) 0.75
Pleural carcinosis confirmed by adjuvant cytological methods: a case report. Diagn Cytopathol (1998) 0.75
The tyrosine-kinase inhibitor imatinib induces long-term remission in a patient with chronic myelogenous leukemia with translocation t(4;22). Leukemia (2007) 0.75
[Aspects of internal medicine]. Radiologe (2000) 0.75
Serum deoxythymidine kinase in myelodysplastic syndromes. Cancer (1994) 0.75
Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide. Leuk Res (2005) 0.75
Acute acalculous cholecystitis complicating oral recontamination after allogeneic bone marrow transplantation. Oncol Rep (2011) 0.75
The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide. Leuk Lymphoma (2005) 0.75
Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis. Ann Hematol (2013) 0.75
[Myelodysplastic syndromes. The epidemiological and etiological aspects]. Dtsch Med Wochenschr (1992) 0.75
An unusual presentation of a common infection. Infection (2012) 0.75
Severe musculoskeletal pain after cyclosporin A treatment in a patient undergoing allogeneic BMT. Oncol Rep (1996) 0.75
Improved prophylaxis against overwhelming postsplenectomy infections. Eur J Haematol (1997) 0.75
[Dynamic MRI of the lumbar spine for the evaluation of microcirculation during anti-angiogenetic therapy in patients with myelodysplastic syndromes]. Rofo (2002) 0.75
[The prognostic significance of serum thymidine kinase in the myelodysplastic syndrome]. Dtsch Med Wochenschr (1996) 0.75
[Vaccination after splenectomy and in asplenia]. Internist (Berl) (1998) 0.75
Primary pancreatic lymphoma--a rare cause of cholestasis leading to surgical treatment. Ann Hematol (2006) 0.75
Testicular infiltration in acute myeloid leukemia with complex karyotype including t(8;21). Ann Hematol (2001) 0.75
[Splenomegaly and portal hypertension of unusual etiology in a 62-year-old patient]. Internist (Berl) (1996) 0.75
Dyshematopoiesis in de novo acute myeloid leukemia: cell biological features and prognostic significance. Leuk Lymphoma (1998) 0.75
[Bone marrow involvement in hematologic neoplasms and solid tumors]. Radiologe (2000) 0.75
[Myelodysplastic syndromes]. Internist (Berl) (2010) 0.75
[Role of aggressive treatment strategies for myelodysplastic syndromes]. Praxis (Bern 1994) (1999) 0.75
Massive extramedullary disease progression in a patient with stable multiple myeloma during G-CSF priming for peripheral blood progenitor mobilization. Oncol Rep (1999) 0.75
Double treatment of severe hepatic veno-occlusive disease after allogeneic peripheral blood progenitor cell transplantation with recombinant tissue plasminogen activator. Thromb Haemost (1997) 0.75
Fatal hyperleukocytic syndrome in a patient with chronic myelomonocytic leukemia. Leuk Res (1997) 0.75